London- August 2024- Imperial College Academic Health Science Centre (AHSC) has appointed Professor Mark Thursz as its Director.
Imperial College AHSC aims to accelerate the translation of scientific breakthroughs into new ways to improve patient care and public health. It is a strategic partnership between Imperial College London, Imperial College Healthcare NHS Trust, The Royal Marsden NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust and The Institute of Cancer Research, London.
Professor Thursz, who took up his post earlier this month, is Professor of Hepatology at Imperial College London and Consultant in Hepatology at St Mary’s Hospital, part of Imperial College Healthcare NHS Trust. He is also Director of the NIHR Imperial Biomedical Research Centre (BRC) – a partnership between Imperial College Healthcare NHS Trust and Imperial College London.
In 1997, Professor Thursz became a consultant in Hepatology at St Mary’s Hospital, where he provides treatment for patients with a wide spectrum of liver diseases. He served as clinical lead for Hepatology for six years and established the Operational Delivery Network for viral hepatitis in North West London.
Also Read: Omnicell Appoints Francois Verdeaux as Global GM
Professor Thursz has gained international renown for his research on viral hepatitis and alcohol-related liver disease. He led the European Association for Study of the Liver (EASL) from 2011 – 2013 and authored the European guidelines on Alcohol-Related Liver Disease. In 2011, Professor Thursz launched the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFCA) programme to address barriers that prevent the control and elimination of viral hepatitis in countries with limited resources. He also runs a translational research programme in alcohol-related liver disease.
“Imperial College AHSC does extraordinary work and I am thrilled to be its next Director. There are new global, national and local challenges ahead and problems to help solve. I know the AHSC is more than equipped to meet these challenges and play a leading role in shaping the future of translational medicine.” Said Professor Mark Thursz, Director of Imperial College AHSC.
